Drug intelligence / Profile preview

HRS-5091

Development stage: Phase 1
Lead developer: Hengrui Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

HRS-5091 is an investigational small molecule drug developed by Jiangsu Hengrui Pharmaceuticals. It acts as a hepatitis B virus (HBV) capsid inhibitor, targeting the HBV capsid to disrupt viral assembly and replication. The drug is being developed primarily for the treatment of chronic hepatitis B and has completed Phase 1 clinical trials evaluating its safety, tolerability, pharmacokinetics, and potential for drug-drug interactions in healthy volunteers and patients with chronic hepatitis B. Its route of administration is oral[1][3][7].

Targets

HBc (Hepatitis B virus core protein)

Beyond the preview

Go deeper on HRS-5091.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRS-5091.

Explore the full profile